Dr. Mahony has been a director since December 2017. From 2011 until her retirement in August 2018, she served as Senior Vice President and President of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company. Prior to that, she was Senior Vice President, Human Resources and Diversity. During her time at Lilly, Dr. Mahony has held roles in global marketing, product development, six sigma and general management, including global brand development leader for duloxetine (Cymbalta®) and fluoxetine (Prozac®), and country manager for Canada. Dr. Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Schering-Plough, Amgen and Bristol-Myers Squibb with global and direct responsibility for the US, Japan, China, Europe and Canada. Currently she serves as a member of the board of directors of two publicly traded companies, Zymeworks, Inc. and Horizon Therapeutics plc, and she previously served on the board of directors of Vifor Pharma. Dr. Mahony earned both Bachelor of Science and PhD degrees in pharmacy from Aston University in the UK, which also awarded her an honorary doctorate degree. She received an MBA from the London School of Business, and in 2010, she was recognized as one of the Indianapolis Business Journal's “Women of Influence.”